ALS Research Capitalizes on Stem Cells.

A recent Mt. Sinai study for ALS is set to enter phase one clinical trials.

Researchers at the Cedars-Mt. Sinai Regenerative Medicine Institute, led by Dr. Robert H. Baloh, have devised a method to study and develop potential treatments for Amyotrophic Lateral Sclerosis [ALS] by utilizing patients’ stem cell-derived neurons.  In an example of what is referred to as translational genomics, researchers extract autologous (the patient’s own) stem cells, correct the defective gene causing the disease, and then, in a potential treatment protocol, transplant the cells back into the patient to reverse neural degeneration.

Autologous stem cells are vital to ALS research not only in developing translational genomic treatments, but also in the preparation of the disease-on-a-dish models that were utilized to study the disease on a genetic and molecular level.  According to Dr. Clive Svendsen, Director of the Regenerative Medicine Institute, “ALS may be the cruelest, most severe neurological disease, but I believe the stem cell approach used in this collaborative effort holds the key to unlocking the mysteries of this and other devastating disorders.”

The research is an example of how scientists are gaining insights that will facilitate more effective treatments leading to better outcomes.  To learn more about the value of preserving your own mesenchymal stem cells for use in future therapies and how to bank your own stem cells through a non-evasive and affordable method by recovering your dental pulp stem cells, visit StemSave or call 877-783-6728 (877-StemSave) today.

 

 

To view the full article, click here.

 

 

The Future of Regenerative Medicine is Now™.